Gambaran Umum
Emergent BioSolutions Inc., headquartered in Gaithersburg, Maryland, USA, is a global biopharmaceutical company primarily focused on developing and manufacturing vaccines and antibody therapeutics for infectious diseases, as well as opioid overdose treatments. The company plays a pivotal role in public health with key products like BioThrax (Anthrax Vaccine Adsorbed), the only FDA-licensed vaccine against anthrax disease, and Narcan (naloxone HCI) Nasal Spray for emergency treatment of opioid overdose. Emergent also provides specialized products and services to governmental and civilian clients, concentrating on medical countermeasure development and stockpiling for biosecurity purposes. Their involvement in the Biomedical Advanced Research and Development Authority (BARDA)'s initiatives highlights their commitment to addressing biosecurity and public health emergencies.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Emergent BioSolutions Inc. per 2025 Jun 30 adalah 851.60 MM.
- Nilai operating income untuk Emergent BioSolutions Inc. per 2025 Jun 30 adalah 118.00 MM.
- Nilai net income untuk Emergent BioSolutions Inc. per 2025 Jun 30 adalah 139.50 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 851.60 | 118.00 | 139.50 |
2025-03-31 | 965.40 | -41.60 | -131.60 |
2024-12-31 | 1,043.60 | -52.20 | -190.60 |
2024-09-30 | 1,125.50 | -113.80 | -208.80 |
2024-06-30 | 1,102.20 | -165.80 | -587.00 |
2024-03-31 | 1,185.40 | 9.30 | -565.30 |
2023-12-31 | 1,049.30 | -168.10 | -760.50 |
2023-09-30 | 1,102.90 | -122.90 | -778.00 |
2023-06-30 | 1,072.30 | -163.30 | -601.70 |
2023-03-31 | 974.30 | -253.80 | -394.10 |
2022-12-31 | 1,117.50 | -109.30 | -211.60 |
2022-09-30 | 1,491.40 | 195.90 | 33.30 |
2022-06-30 | 1,580.50 | 208.50 | 87.70 |
2022-03-31 | 1,757.20 | 307.60 | 157.50 |
2021-12-31 | 1,773.60 | 386.00 | 219.50 |
2021-09-30 | 1,652.50 | 336.30 | 227.00 |
2021-06-30 | 1,708.70 | 488.90 | 299.20 |
2021-03-31 | 1,705.90 | 602.00 | 387.30 |
2020-12-31 | 1,577.30 | 499.20 | 305.80 |
2020-09-30 | 1,332.70 | 342.60 | 166.60 |
2020-06-30 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | -2.46 | -2.46 |
2024-12-31 | -3.60 | -3.60 |
2024-09-30 | -3.98 | -3.98 |
2024-06-30 | -11.26 | -11.25 |
2024-03-31 | -10.93 | -10.93 |
2023-12-31 | -14.85 | -14.85 |
2023-09-30 | -15.37 | -15.37 |
2023-06-30 | -11.99 | -11.99 |
2023-03-31 | -7.89 | -7.89 |
2022-12-31 | -4.22 | -4.22 |
2022-09-30 | 0.65 | 0.65 |
2022-06-30 | 1.69 | 1.69 |
2022-03-31 | 2.98 | 2.97 |
2021-12-31 | 4.10 | 4.06 |
2021-09-30 | 4.24 | 4.18 |
2021-06-30 | 5.61 | 5.50 |
2021-03-31 | 7.30 | 7.12 |
2020-12-31 | 5.80 | 5.68 |
2020-09-30 | 3.18 | 3.11 |
2020-06-30 | 3.28 | 3.19 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Emergent BioSolutions Inc. per 2025 Jun 30 adalah 169.00 MM.
- Nilai cash from investing activities untuk Emergent BioSolutions Inc. per 2025 Jun 30 adalah 217.30 MM.
- Nilai kas dari aktivitas pendanaan untuk Emergent BioSolutions Inc. per 2025 Jun 30 adalah -186.60 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | 169.00 | 217.30 | -186.60 |
2025-03-31 | 110.10 | 195.50 | -231.10 |
2024-12-31 | 58.70 | 125.20 | -190.00 |
2024-09-30 | 170.70 | 85.20 | -185.80 |
2024-06-30 | 77.00 | -45.70 | -48.50 |
2024-03-31 | -84.90 | 216.60 | -484.50 |
2023-12-31 | -206.30 | 212.30 | -535.70 |
2023-09-30 | -145.60 | 178.30 | -187.30 |
2023-06-30 | -279.60 | -74.40 | 85.00 |
2023-03-31 | -180.80 | -364.20 | 541.20 |
2022-12-31 | -34.10 | -381.30 | 481.20 |
2022-09-30 | 201.20 | -381.70 | 18.10 |
2022-06-30 | 291.90 | -165.30 | -216.20 |
2022-03-31 | 278.70 | -201.10 | -189.30 |
2021-12-31 | 320.20 | -224.10 | -141.00 |
2021-09-30 | 237.20 | -214.30 | -33.30 |
2021-06-30 | 325.70 | -204.80 | 58.80 |
2021-03-31 | 483.30 | -182.90 | 67.30 |
2020-12-31 | 536.90 | -151.90 | 69.50 |
2020-09-30 | 413.00 | -151.10 | 13.90 |
2020-06-30 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah -2.64.
- p/libro untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah 0.63.
- p/tbv untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah 5.14.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -2.64 | 0.63 | 5.14 |
2025-03-31 | 0.52 | -13.54 | |
2024-12-31 | 0.99 | -53.32 | |
2024-09-30 | -0.69 | 1.05 | -2.74 |
2024-06-30 | -0.65 | 0.55 | 3.22 |
2024-03-31 | -0.18 | 0.21 | 1.63 |
2023-12-31 | -0.16 | 0.13 | 0.80 |
2023-09-30 | -0.28 | 0.18 | 1.18 |
2023-06-30 | -0.95 | 0.32 | 1.02 |
2023-03-31 | -2.32 | 0.38 | |
2022-12-31 | 0.41 | 1.17 | |
2022-09-30 | 0.69 | 1.47 | |
2022-06-30 | 0.99 | 2.05 | |
2022-03-31 | 8.98 | 1.28 | 2.63 |
2021-12-31 | 10.30 | 1.54 | 3.67 |
2021-09-30 | 8.98 | 1.74 | 4.17 |
2021-06-30 | |||
2021-03-31 | 5.15 | 1.31 | 3.28 |
2020-12-31 | 6.48 | 1.37 | 3.83 |
2020-09-30 | 11.84 | 1.58 | 6.43 |
2020-06-30 | 11.57 | 1.64 | 9.37 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah -0.07.
- EBIT (3 tahun) / EV untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah -0.46.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.07 | -0.46 |
2025-03-31 | -0.17 | -0.44 |
2024-12-31 | -0.17 | -0.37 |
2024-09-30 | -0.48 | -0.34 |
2024-06-30 | -0.47 | -0.20 |
2024-03-31 | -0.83 | -0.24 |
2023-12-31 | -0.83 | -0.12 |
2023-09-30 | -0.55 | -0.00 |
2023-06-30 | -0.28 | 0.04 |
2023-03-31 | -0.17 | 0.13 |
2022-12-31 | 0.08 | 0.15 |
2022-09-30 | 0.09 | 0.15 |
2022-06-30 | 0.12 | 0.15 |
2022-03-31 | 0.13 | 0.13 |
2021-12-31 | 0.11 | 0.09 |
2021-09-30 | 0.13 | 0.07 |
2021-06-30 | ||
2021-03-31 | 0.22 | 0.10 |
2020-12-31 | 0.18 | 0.08 |
2020-09-30 | 0.09 | 0.05 |
2020-06-30 | 0.09 | 0.05 |
Efektivitas Manajemen
- roa untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah -0.09.
- roe untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah -0.34.
- roic untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah -0.11.
- croic untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah 0.06.
- ocroic untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah 0.09.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.09 | -0.34 | -0.11 | 0.06 | 0.09 |
2025-03-31 | -0.11 | -0.29 | -0.16 | -0.01 | 0.05 |
2024-12-31 | -0.11 | -0.32 | -0.18 | 0.06 | 0.14 |
2024-09-30 | -0.31 | -0.61 | -0.46 | -0.01 | 0.06 |
2024-06-30 | -0.19 | -0.47 | -0.36 | -0.22 | -0.05 |
2024-03-31 | -0.24 | -0.55 | -0.50 | -0.35 | -0.14 |
2023-12-31 | -0.26 | -0.53 | -0.42 | -0.08 | -0.08 |
2023-09-30 | -0.22 | -0.40 | -0.32 | -0.14 | -0.15 |
2023-06-30 | -0.15 | -0.27 | -0.26 | -0.11 | -0.12 |
2023-03-31 | -0.08 | -0.14 | -0.15 | -0.00 | -0.07 |
2022-12-31 | 0.02 | 0.04 | 0.02 | -0.06 | 0.08 |
2022-09-30 | 0.03 | 0.06 | 0.02 | -0.07 | 0.09 |
2022-06-30 | 0.05 | 0.10 | 0.04 | -0.04 | 0.12 |
2022-03-31 | 0.08 | 0.15 | 0.06 | -0.05 | 0.11 |
2021-12-31 | 0.08 | 0.16 | 0.09 | -0.02 | 0.10 |
2021-09-30 | 0.11 | 0.24 | 0.09 | -0.00 | 0.13 |
2021-06-30 | 0.12 | 0.25 | 0.12 | 0.07 | 0.14 |
2021-03-31 | 0.17 | 0.36 | 0.16 | 0.15 | 0.20 |
2020-12-31 | 0.13 | 0.28 | 0.13 | 0.19 | 0.23 |
2020-09-30 | 0.07 | 0.16 | 0.08 | 0.13 | 0.19 |
2020-06-30 | 0.07 | 0.17 | 0.09 | 0.05 | 0.15 |
Gross Margins
- marjin kotor untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah 0.37.
- marjin bersih untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah -0.14.
- marjin operasi untuk Emergent BioSolutions Inc. pada 2025 Jun 30 adalah -0.04.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.37 | -0.14 | -0.04 |
2025-03-31 | 0.40 | -0.18 | 0.04 |
2024-12-31 | 0.26 | -0.19 | -0.10 |
2024-09-30 | 0.29 | -0.53 | -0.08 |
2024-06-30 | 0.35 | -0.48 | -0.01 |
2024-03-31 | 0.24 | -0.72 | -0.17 |
2023-12-31 | 0.22 | -0.69 | -0.18 |
2023-09-30 | 0.19 | -0.57 | -0.21 |
2023-06-30 | 0.11 | -0.57 | -0.21 |
2023-03-31 | 0.21 | -0.41 | -0.32 |
2022-12-31 | 0.40 | 0.04 | 0.14 |
2022-09-30 | 0.39 | 0.04 | 0.14 |
2022-06-30 | 0.41 | 0.06 | 0.14 |
2022-03-31 | 0.45 | 0.09 | 0.18 |
2021-12-31 | 0.44 | 0.13 | 0.22 |
2021-09-30 | 0.52 | 0.14 | 0.20 |
2021-06-30 | 0.52 | 0.18 | 0.29 |
2021-03-31 | 0.57 | 0.23 | 0.35 |
2020-12-31 | 0.20 | 0.32 | |
2020-09-30 | 0.51 | 0.13 | 0.23 |
2020-06-30 | 0.51 | 0.14 | 0.24 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1367644 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |